SCHEMBL14507356

SCHEMBL14507356

Cn1cc(-c2cnc3c(Nc4cc5ccccc5s4)nccn23)cn1

nearest known ligand 0.63

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 9/20 0.63
▸ AURKB Q96GD4 9/20 0.63
▸ CHEK1 O14757 3/20 0.41
▸ TTK P33981 2/20 0.39
▸ FLT3 P36888 6/20 0.39
▸ PTK6 Q13882 1/20 0.37
▸ NEK2 P51955 1/20 0.36
▸ CCNA2 P20248 1/20 0.36
▸ CDK2 P24941 1/20 0.36
▸ LCK P06239 1/20 0.35
▸ RPS6KA3 P51812 1/20 0.35
▸ EPHB4 P54760 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12404527 0.87 AURKB (0.62) AURKAAURKBCHEK1TTKFLT3
SCHEMBL8236220 0.82 AURKA (0.56) AURKAAURKBCHEK1TTKFLT3
SCHEMBL15146142 0.82 AURKB (0.71) AURKAAURKBCHEK1TTKFLT3
SCHEMBL8240162 0.81 AURKA (0.62) AURKAAURKBTTKFLT3PTK6
SCHEMBL8239874 0.81 AURKA (0.69) AURKAAURKBCHEK1TTKFLT3
SCHEMBL8247273 0.80 AURKA (0.69) AURKAAURKBCHEK1TTK
SCHEMBL8241664 0.80 AURKA (0.57) AURKAAURKBCHEK1TTKFLT3
SCHEMBL14507223 0.80 AURKA (0.57) AURKAAURKBCHEK1TTKFLT3
SCHEMBL12404516 0.80 AURKB (0.74) AURKAAURKBCHEK1TTKFLT3
SCHEMBL12404518 0.80 AURKA (0.60) AURKAAURKBCHEK1TTKFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007058942-A2 IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS SCHERING CORPORATION (US) 2007-05-24 — — WO disclosed
US-20070117804-A1 Imidazopyrazines as protein kinase inhibitors SCHERING CORPORATION 2007-05-24 — — US disclosed
US-20070117804-A1 Imidazopyrazines as protein kinase inhibitors SCHERING CORPORATION 2007-05-24 — — US disclosed
WO-2007056468-A1 METHODS FOR INHIBITING PROTEIN KINASES SCHERING CORPORATION (US) 2007-05-18 — — WO disclosed
US-20070105864-A1 Methods for inhibiting protein kinases SCHERING CORPORATION 2007-05-10 — — US disclosed
US-20070105864-A1 Methods for inhibiting protein kinases SCHERING CORPORATION 2007-05-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117804-A1 Imidazopyrazines as protein kinase inhibitors CHEK1, CHEK2, CDKN1A AURKA 41/4885AURKB 138/4885CHEK1 1/4885
US-20070105864-A1 Methods for inhibiting protein kinases PIM1, PIM2, PIM3 AURKA 5/4885AURKB 24/4885CHEK1 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback